EKF Diagnostics set for record month
Cardiff-headquartered EKF Diagnostics is on track for a record month thanks to growth from its core business and continued demand for Covid-19 sample collection kits.
The company said that a significantly improved performance in the core business based on October orders, together for the PrimeStore MTM Covid-19 sample collection device, meant revenues and profits were expected to reach record levels for the month.
EKF added that its full-year performance remained in-line with management expectations, which have already been revised upwards several times this year.
The PrimeStore MTM sample collection device, deactivates viruses, bacteria, fungi and mycobacterium tuberculosis allowing safe sample handling and transport, greatly reducing risk of infection. It was invented in 2006 in preparation for a worldwide pandemic.
The device has recently been successfully evaluated for effective SARS-CoV-2 inactivation in a study published by Public Health England (PHE).
In a statement, the company said: “Due to the continued demand for PrimeStore MTM and the improving performance of our core business the board remains confident of delivering on the strong full year performance reflected in previously revised management expectations.
“Whilst it is too early to make further revisions to these performance expectations, trading in October is expected to suggest a strong Q4 performance.”